The pharmacokinetics of midazolam in patients with congestive heart failure.
The disposition of midazolam was investigated in six patients with congestive heart failure (CHF) and six age- and weight-matched healthy subjects by administering two single doses of the drug (3.75 mg i.v. and 7.5 mg p.o.) separated by 1 week. Serial blood samples were collected for 24 h after each dose and plasma was assayed for midazolam by GC-MS. In the CHF patients, the elimination half-life was prolonged (4 to 4.5 vs less than 3 h), the systemic clearance was lowered (376 vs 551 ml min-1) and the peak plasma drug concentration after the p.o. dose was higher (76 vs 42 ng ml-1). The systemic availability (45 vs 41%), the steady state volume of distribution (111 vs 108 l) and the time of peak plasma drug concentration after the p.o. dose (0.9 vs 0.9 h) were unchanged. The predominant effect of CHF was on the clearance of midazolam which was decreased by 30%. The drug was well tolerated and did not cause any adverse effects.
Patel
I H
IH
Department of Drug Metabolism, Hoffmann-La Roche Inc., Nutley, NJ 07110.
Soni
P P
PP
Fukuda
E K
EK
Smith
D F
DF
Leier
C V
CV
Boudoulas
H
H
D000328:Adult; D001794:Blood Pressure / Q000187:drug effects; D005260:Female; D008401:Gas Chromatography-Mass Spectrometry; D006207:Half-Life; D006333:Heart Failure / Q000378:metabolism*; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008874:Midazolam / Q000008:administration & dosage / Q000493:pharmacokinetics*; D008875:Middle Aged; D010101:Oxygen Consumption / Q000187:drug effects
D008874:Midazolam